Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).
Nakasone H, Terasako-Saito K, Hirano T, Wake A, Shimizu S, Kurita N, Yamazaki E, Usuki K, Akazawa K, Kanda J, Minauchi K, Yamamoto G, Tanimoto S, Kamoshita M, Yokoyama Y, Miyaoka E, Ota S, Kako S, Izutsu K, Kanda Y.
Nakasone H, et al. Among authors: kurita n.
Hematol Oncol. 2018 Feb;36(1):202-209. doi: 10.1002/hon.2452. Epub 2017 Jul 6.
Hematol Oncol. 2018.
PMID: 28681529